Bunbury embraces Compassionate Communities Charter
The City of Bunbury has taken a positive step in growing compassion by endorsing a Compassionate Bunbury Charter. The Charter...
Continue reading
This website may not work correctly in Internet Explorer. We recommend switching to a more secure modern web browser such as Microsoft Edge which is already installed on your computer.
Perron Institute’s Media Centre displays media statements and is the central point of contact for journalists and media outlets seeking expert comments, information about research developments and other information.
All media enquiries should be directed to Perron Institute’s Communications Manager Tennille Kroemer on +61 426 044 223 or tennille.kroemer@perron.uwa.edu.au.
This contact information is for media outlets, journalists and producers only. For all other enquiries, visit the Perron Institute contact page.
The City of Bunbury has taken a positive step in growing compassion by endorsing a Compassionate Bunbury Charter. The Charter...
Clinical Professor David Blacker’s recognition as a Member of the Order of Australia (AM) for services to medicine and neurological...
A Perron Institute led team developing a new neuroprotective therapy and diagnostic to reduce disability in babies suffering brain injury...
Boxing training has become a popular form of exercise for people with Parkinson’s but until now, there has been little...
Raising $100,000 for Australians living with Parkinson’s disease is the goal of a four-person team soon to embark on a...
A research project to build capacity for transcranial magnetic stimulation (TMS) to treat youth suffering from mental health disorders such...
Molecular genetics research to develop more effective treatments for the neurodegenerative disorder spinal muscular atrophy (SMA) has received funding from...
A neuroprotective drug candidate being trialled in Western Australia for stroke may also be beneficial for treating Alzheimer’s disease. The...
The Perron Institute’s newest Director, Emeritus Professor John Finlay-Jones has a background in clinical microbiology and immunology. He also made...
WA-based biotechnology company Argenica Therapeutics has attracted a $1.2 million grant for work on a potential therapeutic drug for mild and moderate...
A renowned Western Australian ophthalmologist who led the development of a revolutionary intervention to treat the sight stealing eye disease,...
Participant dosing in the Phase 1 clinical trial to test the safety of ARG-007 has been completed, with healthy participants...
Stay up to date with our latest news and announcements.